Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think that with Charite Berlin we have a strong partner in Germany!
http://kks.charite.de/
This is the "homepage" for the clinical studies - you find SUNRISE with: nsclc or sunrise or pphm or doxetacel nsclc.....
weather is bad in Austria!
CP - is that the same linke you found in France?
http://www.anticancerfund.org/fr/trials/phase-3-study-of-bavituximab-plus-docetaxel-versus-docetaxel-alone-in-patients-with-late-stag
GERMANY - and you finde also: PPHM 1202 Sunrise
http://cccc.charite.de/forschung/klinische_studien/solide_tumorerkrankungen/lungentumore/
After searching under "Google.DE" i found that (i´m from Austria and i usually use .AT): i seached for " Krebsstudie sunrise nsclc"
Charite Campus Benjamin Franklin / Prof. U. Keilholz
http://www.charite.de/charite/organisation/standorte/campus_benjamin_franklin_cbf/
Than i seached for SUNRISE and got that:
http://www.charite.de/metas/suche/?search_query_gcs=Sunrise&as_sitesearch_box=
click on the first link and you will find our SUNRISE!!!!!
ELCC 2015 - 15-18 April 2015 in Geneva with David Carbone
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105569555
http://cancer.osu.edu/research/cancerresearch/researchprograms/experimentaltherapeutics/members/Pages/index.aspx?mid=3532
From that article - FEB. 2013
Conclusions
In reviewing the development history of bavituximab it is difficult to understand the rationale for much of what Peregrine has done; specifically, the large number of open-label studies, the small number of randomized studies and the fact that the randomized trials were underpowered. Moreover, the company has not provided statistical information (e.g., power to detect differences of a stated magnitude) for any of its randomized trials leading one to wonder if the trials were so underpowered that the company was uncomfortable sharing this information. Then there are the results from the failed randomized trials in 2nd-line NSCLC and 1st-line pancreatic cancer which have seemingly been ignored by the company. Finally, the development history of bavituximab suggests reluctance on Peregrine's part to test the drug in a well-powered study. The party is over for Peregrine, investors are losing patience and it's time to move on.
thats the link - i think: from Feb 2013!!!
http://seekingalpha.com/article/1223751-peregrine-pharmaceuticals-bavituximab-its-time-to-throw-in-the-towel
136 study loc. up up up
Hmmmm back at 1,55$
thought to get some under 1,50 today
Liver (Cancer) Conf. 2014: i found this
7 - 8 Nov.
http://www.aasld.org/livermeeting/Pages/default.aspx
and this
11 - 13 Sep.
http://www.aleh2014.com/eng/index.htm
1,55 PM with 600 vol.
thx for the link! and stay Long!
just one "unaware" question from me (i hope): what does upstream / downstream means in the context with pphm/bavi?
Sponsor:
University of Texas Southwestern Medical Center
http://www.clinicaltrials.gov/ct2/show/NCT01264705?term=bavituximab&rank=12
That´s what i know!
Thx - found it so i think news will come therefore from UTSW and not from Bayer
Bayer is not the sponsor of this study - that could be the reason!?
Right????
Hi CP,
i can´t find the Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer at the Bayer Homepage:
http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php?search=NCT01264705&btnSubmit=Search&product=&overall_status=&country=&phase=&condition=&results=0&trials=0&num=10&show=1
Any ideas; or it is there, but i can´t see/find it???!!!
I hope we get news - sooner or later...
The conf. is in Kyoto/Japan - and ILCA is from Brussels
http://www.ilca2014.org/
placed another buy-order - let´s see........
Kyoto 13:00 – 14:30 Bayer Lunch Symposium is over!
No News found!
CRI Cancer Immunotherapy 2014
http://ir.peregrineinc.com/events.cfm
I hope that! let´s see what Kyoto and San Francisco brings........
Nice weekend - kyoto and San Francisco coming soon!
September is coming very soon and we have a lot short-info on board - i think that are good news! kyoto ins coming...........
Thx for your great Info Shorting - you will never get my 200k pphm keep dreaming my friend!
A final Countdown?
I'm waiting........
Would be interesting if we see a short-attack before Kyoto!!!??? So NO stops but lower buy-limits!
i am certain of it, interesting weeks and months are coming!
I think we will hear news from pphm not at a conference - it will be a ad-hoc-news
hmmmm... nasdaq vol 160k - that is less than i have on my account - pphm is drying out....
From the Programm ELCC 2015:
16. April
Specialty session/ How do we improve the outcome of stage III NSCLC?
Improving stage III outcome: any perspective? Paul de Leyn, BE
PPHM/Dr. Carbone is also at the ELCC 2015 - 15-18 April 2015 in Geneva
2Q 2015 - is that the right time for you CP
The evolving role of immunotherapy for lung cancer
http://www.esmo.org/Conferences/ELCC-2015-Lung-Cancer/Programme
CP, do you mean ESMO in Geneva Nov. 2014??? Immuno-Oncology
http://www.esmo.org/Conferences/Immuno-Oncology-2014
Programm: 21 - 22 Nov.
22. Nov. at 11:30 Dr. Carbone: The immune system and lung cancer
http://www.peregrineinc.com/about-us/medical-and-scientific-advisors.html
http://www.esmo.org/Conferences/Immuno-Oncology-2014/Programme
So, than let´s hope, that pphm has the gold standard - i´m a believer!
i don´t know that - but i hope so!
Yes, please!!!!